Sarepta initiates screening for Phase 3 study for gene therapy SRP 9003

Shidlovski Sarepta Therapeutics ( NASDAQ: SRPT ) said it has initiated screening in a Phase 3 clinical study of its gene therapy candidate SPR 9003 for the treatment of limb girdle muscular dystrophy type 2E/R4, or LGMD2E. The study will enroll 15 patients, both ambulatory and non ambulatory, aged four and older, and will utilize commercially representative process SRP 9003 material, the company said .

More on Sarepta Therapeutics Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data Concerns Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript Sarepta Therapeutics, Inc. 2023 Q3 Results Earnings Call Presentation Sarepta hopeful on Elevidys label expansion Sarepta Therapeutics provides Q4 and FY forecast.